兰州大学机构库 >第二临床医学院
我国类风湿关节炎患者应用肿瘤坏死因子抑制剂现况调查
Alternative TitleSurvey of tumor necrosis factor inhibitors application in patients with rheumatoid arthritis in China
2012-04-18
Source Publication北京大学学报(医学版)   Impact Factor & Quartile Of Published Year  The Latest Impact Factor & Quartile
ISSN1671-167X
Volume44Issue:2Pages:182-187
Abstract目的:了解我国类风湿关节炎(rheumatoid arthritis,RA)患者应用肿瘤坏死因子(tumor necrosis factor,TNF)抑制剂的现状以及影响其应用的因素。方法:采用多中心现况调查问卷调查的方法,记录入选者的一般情况和应用TNF抑制剂的情况,计算患者应用TNF抑制剂的费用,分析我国TNF抑制剂的应用现状及影响其应用的相关因素。结果:2009年7月至2010年11月期间,共有全国范围内的21家大型医院风湿免疫科就诊的1 095位RA患者完成问卷,其中112位患者应用了TNF抑制剂(infliximab,商品名类克或etanercept,商品名益赛普)进行治疗,占总研究...
Other AbstractOBJECTIVE: To investigate the current status of tumor necrosis factor (TNF) inhibitors application in rheumatoid arthritis (RA) patients in China and to analyze the related factors.METHODS: A retrospective survey was conducted in 21 hospitals from different parts of China. The patients with RA were randomly enrolled. Data of their social backgrounds, clinical conditions, usage and adverse effects of TNF inhibitors were collected. The costs of TNF inhibitors and the indirect costs of the disease were calculated. A multivariate Logistic regression analysis was performed to analyze the factors related to TNF inhibitors application.RESULTS: In the study, 1 095 RA patients from July 2009 to November 2010 were enrolled, of whom 112 had received TNF inhibitors, representing 10.2% of the total patients. The patients who received etanercept and infliximab were 7.4% (86/1 095) of the patients and 2.4% (26/1 095), respectively. There were 0.5% of the patients (5/1 095) who had received both of the TNF inhibitors. The patients who had accepted etanercept and treatment duration for less than 3 months and 3-6 months accounted for 38.5% and 25.0% respectively, while those treated with Infliximab were 38.1%. Their health assessment questionnaire (HAQ) scores were 1.1, 0.5 and 0.1, corresponding to treatment duration of infliximab for less than 3, 3-6 and 6-9 months and those were 1.3, 1.0, 0.3 corresponding to treatment duration of etanercept, respectively. Infliximab costs were RMB 24 525.0, 69 300.0 and 96 800.0 Yuan and etanercept costs were RMB 7 394.8, 9 158.6, 54 910.9 Yuan, respectively. Indirect costs for RA patients who accepted infliximab for less than 3, 3-6 and 6-9 months were RMB 365.6, 0 and 158.9 Yuan and those who accepted etanercept were RMB 2 158.4, 288.5 and 180.1 Yuan, respectively. Allergy and infection were the main side-effects of etanercept and both happened in 3.5% of all the patients. Liver damage happened in 2.3% of all the patients, while allergy and infection happened in 6.5% of all the patients who accepted infliximab. Logistic regression analysis showed that patients with higher education experience increased the odds of entering the TNF inhibitors group (OR: 1.292, 95%CI: 1.132-1.473, P=0.000).CONCLUSION: About one-tenth of RA patients in China have accepted TNF inhibitors. Higher education experience is the key factor for using TNF inhibitors.
Keyword关节炎,类风湿 肿瘤坏死因子 问卷调查 药费支出
Subject AreaGeriatrics & Gerontology ; Pharmacology & Pharmacy ; Immunology ; Rheumatology ; Health Care Sciences & Services ; Biochemistry & Molecular Biology
Publication PlaceBEIJING
Indexed ByPubMed ; MEDLINE ; CSCD
Language中文
First Inst
Funding Project国家科技支撑计划
Host of Journal北京大学
Project Number“十一五”国家科技支撑计划项目(2008BAI59B01)资助~~
CSCD IDCSCD:4503645
Funding OrganizationMOST
PMID 22516984
IRIDCNKI:0050490
Department
北京大学人民医院风湿免疫科;
北京大学首钢医院多顶街社区卫生中心全科;
山西医科大学第二医院风湿免疫科;
包头医学院第一附属医院风湿免疫科;
中日友好医院风湿免疫科;
第四军医大学西京医院风湿免疫科;
兰州大学第二医院风湿免疫科;
河北医科大学第二医院风湿免疫科;
河北医科大学第三医院风湿免疫科;
北京大学第三医院风湿免疫科...更多
Citation statistics
Cited Times:2[CSCD]   [CSCD Record]
Document Type期刊论文
Identifierhttps://ir.lzu.edu.cn/handle/262010/174478
Collection第二临床医学院
Recommended Citation
GB/T 7714
王秀茹,苏茵,安媛,等. 我国类风湿关节炎患者应用肿瘤坏死因子抑制剂现况调查[J]. 北京大学学报(医学版),2012,44(2):182-187.
APA 王秀茹.,苏茵.,安媛.,周云杉.,张晓盈.,...&栗占国.(2012).我国类风湿关节炎患者应用肿瘤坏死因子抑制剂现况调查.北京大学学报(医学版),44(2),182-187.
MLA 王秀茹,et al."我国类风湿关节炎患者应用肿瘤坏死因子抑制剂现况调查".北京大学学报(医学版) 44.2(2012):182-187.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Altmetrics Score
Google Scholar
Similar articles in Google Scholar
[王秀茹]'s Articles
[苏茵]'s Articles
[安媛]'s Articles
Baidu academic
Similar articles in Baidu academic
[王秀茹]'s Articles
[苏茵]'s Articles
[安媛]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[王秀茹]'s Articles
[苏茵]'s Articles
[安媛]'s Articles
Terms of Use
No data!
Social Bookmark/Share
No comment.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.